Abstract
In a double-blind, 2-yr study, 16 pubortal patients with growth retardation after RTx were Iroatod with either Norditropin 4 (gr A) or 8 (gr B) IU/m2/day. We studied the effects of growth hormone therapy (GHRx) on: growth (height SDS for ngo (HSDSCA)), bono age (BA), renal graft function (GFR. by I125-Thalamalo, In ml/min/1.73m2) and renal plasma (low (RPF. by I131 -Hippuran, in ml/mtn/1.73m2), bone mineral content (BMC, in (mm Ai eq/mm3)× 103). glucose tolerance tosi (OGTT), plasma IGF-I and -II levels and -binding proteins (IGFBP's). Growth during GHRx was also compared with the 2-year-growth of matched (paired) control patients. Mean (SD) age and BA at start: gr A 15.6(2.6) and 12.6(2.4) yr; gr B 15.7(1.9) and 12.3(2.1) yr.
Results (expressed as mean (SD) or mean):
Growth: HSDSCA improved significantly in both gr A and gr B (P<0.0001), without difference between gr A and B. Compared to the matched control patients our study patients showed a significantly better growth during GHRx: mean (SD) height increment during 2 yr waa 15.3(5.7) cm in GHRx patients versus 6.4(3.8) cm in control patients (P<0.002). BA: Bone maturation was similar for gr A and B and the ΔBA/ΔCA ratio was <1 during GHRx. GFR and RPF: Mean values remained stable during 1 yr of GHRx. However, 5 patients had renal problems during the 2 years; 2 had one episode of acute renal rejection (after 7 and 15 mo, resp.) with restoration of renal function after a course of high dose prednisone, 3 showed chronic vascular rejection with decreasing renal function (after 10, 11, and 21 mo, resp.). OGTT: Glucose levels did not change after 5 mo, but all insuline levels were sign, higher during GHRx (P<0.04); no signs of impaired OGTT. BMC: A continuing and sign, increase in BMC was found (P<0.0001). IGF-1 Mean IGF-1 SDS for BA increased sign, and similarly in gr A (liom −0.11 to 1.82) and gr B (from 0.21 to 1.93)(P<0.0001).
Conclusion: GHRx with 4 IU/m2/day results in a significant and sustained improvement of height patients. Bone maturation was unaffected. The higher GH dose old IU/m2/day had similar results. This strongly indicates that GHRx results in an improved final height.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hokken-Koeloqa, A., de Muinck Keizer-Schrama, S., Wolff, E. et al. TWO YEAR RESULTS OF GROWTH HORMONE THERAPY IN ADOLESCENTS WITH SHORT STATURE AFTER RENAL TRANSPLANTATION (RTx). Pediatr Res 33 (Suppl 5), S67 (1993). https://doi.org/10.1203/00006450-199305001-00385
Issue Date:
DOI: https://doi.org/10.1203/00006450-199305001-00385